Warner TD - Search Results

1

Sims EC, Rothman MT, Warner TD, Powell ME. Sims EC, et al. Among authors: warner td. Clin Oncol (R Coll Radiol). 2002 Aug;14(4):313-26. doi: 10.1053/clon.2002.0070. Clin Oncol (R Coll Radiol). 2002. PMID: 12206645 Review.

2

Anti-platelet therapy: cyclo-oxygenase inhibition and the use of aspirin with particular regard to dual anti-platelet therapy.

Warner TD, Nylander S, Whatling C. Warner TD, et al. Br J Clin Pharmacol. 2011 Oct;72(4):619-33. doi: 10.1111/j.1365-2125.2011.03943.x. Br J Clin Pharmacol. 2011. PMID: 21320154 Free PMC article. Review.

3

Clopidogrel withdrawal: is there a "rebound" phenomenon?

Sambu N, Warner T, Curzen N. Sambu N, et al. Thromb Haemost. 2011 Feb;105(2):211-20. doi: 10.1160/TH10-08-0554. Epub 2010 Nov 23. Thromb Haemost. 2011. PMID: 21103667 Review.

4

Prostaglandins and the regulation of tumor growth.

Bishop-Bailey D, Calatayud S, Warner TD, Hla T, Mitchell JA. Bishop-Bailey D, et al. Among authors: warner td. J Environ Pathol Toxicol Oncol. 2002;21(2):93-101. J Environ Pathol Toxicol Oncol. 2002. PMID: 12086407 Review.

5

Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic.

Warner TD, Mitchell JA. Warner TD, et al. FASEB J. 2004 May;18(7):790-804. doi: 10.1096/fj.03-0645rev. FASEB J. 2004. PMID: 15117884 Review.

6

Utility of 96-well plate aggregometry and measurement of thrombi adhesion to determine aspirin and clopidogrel effectiveness.

Armstrong PC, Dhanji AR, Truss NJ, Zain ZN, Tucker AT, Mitchell JA, Warner TD. Armstrong PC, et al. Among authors: warner td. Thromb Haemost. 2009 Oct;102(4):772-8. doi: 10.1160/TH09-04-0215. Thromb Haemost. 2009. PMID: 19806265

7

Dual antiplatelet therapy in cardiovascular disease: does aspirin increase clinical risk in the presence of potent P2Y12 receptor antagonists?

Warner TD, Armstrong PC, Curzen NP, Mitchell JA. Warner TD, et al. Heart. 2010 Nov;96(21):1693-4. doi: 10.1136/hrt.2010.205724. Heart. 2010. PMID: 20956485

8

The importance of endothelium-derived mediators to the efficacy of dual anti-platelet therapy.

Warner TD, Armstrong PC, Chan MV, Knowles RB. Warner TD, et al. Expert Rev Hematol. 2016 Mar;9(3):223-5. doi: 10.1586/17474086.2016.1140035. Expert Rev Hematol. 2016. PMID: 26822235 No abstract available.

9

Intimal smooth muscle cells as a target for peroxisome proliferator-activated receptor-gamma ligand therapy.

Bishop-Bailey D, Hla T, Warner TD. Bishop-Bailey D, et al. Among authors: warner td. Circ Res. 2002 Aug 9;91(3):210-7. doi: 10.1161/01.res.0000029080.15742.85. Circ Res. 2002. PMID: 12169646

10

COX-2 selectivity alone does not define the cardiovascular risks associated with non-steroidal anti-inflammatory drugs.

Warner TD, Mitchell JA. Warner TD, et al. Lancet. 2008 Jan 19;371(9608):270-3. doi: 10.1016/S0140-6736(08)60137-3. Lancet. 2008. PMID: 18207021 Review. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

358 results

Search Page